MKMithum Kularatne

Mithum Kularatne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mithum Kularatne has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors

    by Julien Grynblat, Charles Khouri, Alex Hlavaty, Xavier Jaïs, Laurent Savale, Marie Camille Chaumais, Mithum Kularatne, Mitja Jevnikar, Athénaïs Boucly, Fabrice Antigny, et al.

    Background: Pulmonary arterial hypertension (PAH) has been described in patients treated with proteasome inhibitors (PIs). Our objective was to evaluate the association between PIs and PAH.Methods: Characteristics of incident PAH cases previously treated with carfilzomib or bortezomib were analysed from the French pulmonary hypertension registry and the VIGIAPATH programme from 2004 to 2023, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization (WHO) global database (VigiBase) and a meta-analysis of randomised controlled trials.Results: 11 incident cases of PI-associated PAH were identified (six with carfilzomib and five with bortezomib) with a female:male ratio of 2.7:1, a median age of 61 years, and a median delay between PI first exposure and PAH of 6 months. Four patients died (two from right heart failure, one from respiratory distress and one from an unknown cause). At diagnosis, six were in New York Heart Association Functional Class III/IV with severe haemodynamic impairment (median mean pulmonary arterial pressure 39 mmHg, cardiac index 2.45 L·min−1·m−2and pulmonary vascular resistance 7.2 WU). In the WHO pharmacovigilance database, 169 cases of PH associated with PI were reported since 2013 with significant signals of disproportionate reporting (SDR) for carfilzomib, regardless of the definition of cases or control group. However, SDR for bortezomib were inconsistent. The systematic review identified 17 clinical trials, and carfilzomib was associated with a significantly higher risk of dyspnoea, severe dyspnoea and PH compared with bortezomib.Conclusion: PIs may induce PAH in patients undergoing treatment, with carfilzomib emitting a stronger signal than bortezomib, and these patients should be monitored closely.


  • Open Access

    Updated Clinical Classification and Hemodynamic Definitions of Pulmonary Hypertension and Its Clinical Implications

    by Mithum Kularatne, Christian Gerges, Mitja Jevnikar, Marc Humbert, David Montani

    Pulmonary hypertension (PH) refers to a pathologic elevation of the mean pulmonary artery pressure (mPAP) and is associated with increased morbidity and mortality in a wide range of medical conditions. These conditions are classified according to similarities in pathophysiology and management in addition to their invasive hemodynamic profiles. The 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension present the newest clinical classification system and includes significant updates to the hemodynamic definitions. Pulmonary hypertension is now hemodynamically defined as an mPAP > 20 mmHg, reduced from the previous threshold of ≥25 mmHg, due to important insights from both normative and prognostic data. Pulmonary vascular resistance has been extended into the definition of pre-capillary pulmonary hypertension, with an updated threshold of >2 Wood Units (WU), to help differentiate pulmonary vascular disease from other causes of increased mPAP. Exercise pulmonary hypertension has been reintroduced into the hemodynamic definitions and is defined by an mPAP/cardiac output slope of >3 mmHg/L/min between rest and exercise. While these new hemodynamic thresholds will have a significant impact on the diagnosis of pulmonary hypertension, no evidence-based treatments are available for patients with mPAP between 21–24 mmHg and/or PVR between 2–3 WU or with exercise PH. This review highlights the evidence underlying these major changes and their implications on the diagnosis and management of patients with pulmonary hypertension.


  • Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension

    by Mithum Kularatne, Athénaïs Boucly, Laurent Savale, Sabina Solinas, Céline Cheron, Anne Roche, Mitja Jevnikar, Xavier Jaïs, David Montani, Marc Humbert, et al.

    Pulmonary arterial hypertension (PAH) is a severe, progressive pulmonary vasculopathy (Group 1 Pulmonary Hypertension (PH 1)) that complicates the course of many connective tissue diseases (CTD) and significantly impacts the quality and length of life of patients. Due to the various tissues that can be affected by CTD, detailed testing is required to differentiate true PAH from other types of pulmonary hypertension caused by CTD such as left heart disease (Group 2 PH), pulmonary parenchymal disease (Group 3 PH), and chronic thromboembolic pulmonary hypertension (Group 4 PH). CTD-associated PAH is most frequently seen in systemic sclerosis but can also be seen with systemic lupus erythematosus, mixed connective tissues disease, primary Sjogren's syndrome, and inflammatory myopathies. This review discusses the epidemiology of CTD-associated PAH, outlines the complex approach to obtaining a diagnosis, and finishes with an in-depth discussion on the current treatment paradigm with a focus on the pharmacological options available to patients. Focus is placed on the challenges faced in the treatment of CTD-associated PAH, in particular the decreased efficacy and poorer tolerance of pharmacological therapies and includes a discussion on the future investigational treatments that may alter the landscape of therapy. Despite significant advances over the past few decades with new medications and more aggressive treatment algorithms, patients with CTD-associated PAH are less likely to meet treatment targets and continue to have inferior survival compared to those with idiopathic PAH. This review concludes with our opinions on the current state of CTD-associated PAH, highlighting factors that lead to disparate outcomes compared to other forms of PAH, and a discussion on further improvements that may increase quality of life and survival for patients with CTD-associated PAH.


  • Pulmonary arterial hypertension and COVID-19: Piecing the puzzle

    by Fida Charif, Fatima Dakroub, Imad Bou Akl, Mithum Kularatne, David Montani


  • Diagnosis and management of pulmonary veno-occlusive disease

    by Sabina Solinas, Athénaïs Boucly, Antoine Beurnier, Mithum Kularatne, Julien Grynblat, Mélanie Eyries, Peter Dorfmüller, Olivier Sitbon, Marc Humbert, David Montani

    Pulmonary veno-occlusive disease (PVOD) is an orphan disease and uncommon etiology of pulmonary arterial hypertension (PAH) characterized by substantial small pulmonary vein and capillary involvement. PVOD, also known as 'PAH with features of venous/capillary involvement' in the current ESC/ERS classification. In recent years, particular risk factors for PVOD have been recognized, including genetic susceptibilities and environmental factors (such as exposure to occupational organic solvents, chemotherapy, and potentially tobacco). The discovery of biallelic mutations in the EIF2AK4 gene as the cause of heritable PVOD has been a breakthrough in understanding the molecular basis of PVOD. Venous and capillary involvement (PVOD-like) has also been reported to be relatively common in connective tissue disease-associated PAH (especially systemic sclerosis), and in rare pulmonary diseases like sarcoidosis and pulmonary Langerhans cell granulomatosis. Although PVOD and pulmonary arterial hypertension (PAH) exhibit similarities, including severe precapillary PH, it is essential to differentiate between them since PVOD has a worse prognosis and requires specific management. Indeed, PVOD patients are characterized by poor response to PAH-approved drugs, which can lead to pulmonary edema and clinical deterioration. Due to the lack of effective treatments, early referral to a lung transplantation center is crucial.


  • Open Access

    Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives

    by Argyro Vraka, Eleni Diamanti, Mithum Kularatne, Patrick Yerly, Frédéric Lador, John-David Aubert, Benoit Lechartier

    Risk stratification in pulmonary arterial hypertension (PAH) is crucial in assessing patient prognosis. It serves a prominent role in everyday patient care and can be determined using several validated risk assessment scores worldwide. The recently published 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines underline the importance of risk stratification not only at baseline but also during follow-up. Achieving a low-risk status has now become the therapeutic goal, emphasising the importance of personalised therapy. The application of these guidelines is also important in determining the timing for lung transplantation referral. In this review, we summarise the most relevant prognostic factors of PAH as well as the parameters used in PAH risk scores and their evolution in the guidelines over the last decade. Finally, we describe the central role that risk stratification plays in the current guidelines not only in European countries but also in Asian countries.


  • Isolated Pulmonary Arteriovenous Malformations Associated With BMPR2 Pathogenic Variants

    by Mithum Kularatne, Mélanie Eyries, Laurent Savale, Marc Humbert, David Montani